Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amicus Therapeutics (NQ: FOLD ) 10.35 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Amicus Therapeutics < Previous 1 2 3 4 5 Next > Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark September 28, 2023 Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level. Via Investor's Business Daily Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023 September 01, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023 August 29, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer August 21, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics: Q1 Earnings Insights May 10, 2023 Via Benzinga The Latest Analyst Ratings for Amicus Therapeutics March 28, 2023 Via Benzinga Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga Earnings Preview: Amicus Therapeutics February 28, 2023 Via Benzinga Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom August 15, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates August 08, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Second Quarter 2023 Financial Results on August 8, 2023 July 31, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Stock Scores Healthy Relative Strength Upgrade July 20, 2023 On Thursday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, from 78 to 81. Via Investor's Business Daily Amicus Therapeutics Stock Sees Improving Market Leadership; Earns 81 RS Rating July 17, 2023 On Monday, Amicus Therapeutics stock got an upgrade to its Relative Strength (RS) Rating, to 81, up from 74 a day earlier. Via Investor's Business Daily Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union June 27, 2023 Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Now Approved in the European Union for Adults with Late-onset Pompe Disease (LOPD) From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark May 19, 2023 One key metric to look for in a stock is an 80-plus RS Rating. Amicus Therapeutics stock hit that mark, with a jump from 74 to 82 Friday. Via Investor's Business Daily Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics May 10, 2023 The FDA approved Chiesi Group and Protalix BioTherapeutics Inc's (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult Via Benzinga Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates May 10, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Bank of America 2023 Health Care Conference May 02, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce First Quarter 2023 Financial Results on May 10, 2023 May 01, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease April 26, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease March 27, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates March 01, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the Cowen 43rd Annual Health Care Conference February 27, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Positive Long-Term Data from Phase 3 Open-label Extension Study of AT-GAA in Late-Onset Pompe Disease at the 19th Annual WORLDSymposium™ 2023 February 22, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Announce Full-Year 2022 Financial Results on March 1, 2023 February 14, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics Announces Presentations and Posters at the 19th Annual WORLDSymposium™ 2023 February 13, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference February 08, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire 'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month January 25, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec. Via Benzinga Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook January 09, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Amicus Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.